Your browser doesn't support javascript.
loading
Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer.
Painter, Jodie N; O'Mara, Tracy A; Marquart, Louise; Webb, Penelope M; Attia, John; Medland, Sarah E; Cheng, Timothy; Dennis, Joe; Holliday, Elizabeth G; McEvoy, Mark; Scott, Rodney J; Ahmed, Shahana; Healey, Catherine S; Shah, Mitul; Gorman, Maggie; Martin, Lynn; Hodgson, Shirley V; Beckmann, Matthias W; Ekici, Arif B; Fasching, Peter A; Hein, Alexander; Rübner, Matthias; Czene, Kamila; Darabi, Hatef; Hall, Per; Li, Jingmei; Dörk, Thilo; Dürst, Matthias; Hillemanns, Peter; Runnebaum, Ingo B; Amant, Frederic; Annibali, Daniela; Depreeuw, Jeroen; Lambrechts, Diether; Neven, Patrick; Cunningham, Julie M; Dowdy, Sean C; Goode, Ellen L; Fridley, Brooke L; Winham, Stacey J; Njølstad, Tormund S; Salvesen, Helga B; Trovik, Jone; Werner, Henrica M J; Ashton, Katie A; Otton, Geoffrey; Proietto, Anthony; Mints, Miriam; Tham, Emma; Bolla, Manjeet K.
Afiliación
  • Painter JN; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • O'Mara TA; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Marquart L; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Attia J; Hunter Medical Research Institute, John Hunter Hospital, Newcastle, Australia.
  • Medland SE; Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Australia.
  • Cheng T; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Dennis J; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Holliday EG; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • McEvoy M; Hunter Medical Research Institute, John Hunter Hospital, Newcastle, Australia.
  • Scott RJ; Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Australia.
  • Ahmed S; Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Australia.
  • Healey CS; Hunter Medical Research Institute, John Hunter Hospital, Newcastle, Australia.
  • Shah M; Hunter Area Pathology Service, John Hunter Hospital, Newcastle, Australia.
  • Gorman M; Centre for Information Based Medicine, University of Newcastle, Australia.
  • Martin L; School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, Australia.
  • Hodgson SV; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Beckmann MW; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Ekici AB; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Fasching PA; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Hein A; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Rübner M; Department of Clinical Genetics, St George's, University of London, London, United Kingdom.
  • Czene K; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Darabi H; Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Hall P; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Li J; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
  • Dörk T; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Dürst M; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Hillemanns P; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Runnebaum IB; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Amant F; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Annibali D; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Depreeuw J; Hannover Medical School, Gynaecology Research Unit, Hannover, Germany.
  • Lambrechts D; Department of Gynaecology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
  • Neven P; Hannover Medical School, Clinics of Gynaecology and Obstetrics, Hannover, Germany.
  • Cunningham JM; Department of Gynaecology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
  • Dowdy SC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals, KU Leuven - University of Leuven, Leuven, Belgium.
  • Goode EL; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals, KU Leuven - University of Leuven, Leuven, Belgium.
  • Fridley BL; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals, KU Leuven - University of Leuven, Leuven, Belgium.
  • Winham SJ; Vesalius Research Center, VIB, Leuven, Belgium.
  • Njølstad TS; Department of Oncology, Laboratory for Translational Genetics, University Hospitals Leuven, Leuven, Belgium.
  • Salvesen HB; Vesalius Research Center, VIB, Leuven, Belgium.
  • Trovik J; Department of Oncology, Laboratory for Translational Genetics, University Hospitals Leuven, Leuven, Belgium.
  • Werner HM; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals, KU Leuven - University of Leuven, Leuven, Belgium.
  • Ashton KA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Otton G; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, Minnesota.
  • Proietto A; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • Mints M; Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
  • Tham E; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • Bolla MK; Department of Clinical Science, Centre for Cancer Biomarkers, The University of Bergen, Bergen, Norway.
Cancer Epidemiol Biomarkers Prev ; 25(11): 1503-1510, 2016 11.
Article en En | MEDLINE | ID: mdl-27550749
ABSTRACT

BACKGROUND:

The strongest known risk factor for endometrial cancer is obesity. To determine whether SNPs associated with increased body mass index (BMI) or waist-hip ratio (WHR) are associated with endometrial cancer risk, independent of measured BMI, we investigated relationships between 77 BMI and 47 WHR SNPs and endometrial cancer in 6,609 cases and 37,926 country-matched controls.

METHODS:

Logistic regression analysis and fixed effects meta-analysis were used to test for associations between endometrial cancer risk and (i) individual BMI or WHR SNPs, (ii) a combined weighted genetic risk score (wGRS) for BMI or WHR. Causality of BMI for endometrial cancer was assessed using Mendelian randomization, with BMIwGRS as instrumental variable.

RESULTS:

The BMIwGRS was significantly associated with endometrial cancer risk (P = 3.4 × 10-17). Scaling the effect of the BMIwGRS on endometrial cancer risk by its effect on BMI, the endometrial cancer OR per 5 kg/m2 of genetically predicted BMI was 2.06 [95% confidence interval (CI), 1.89-2.21], larger than the observed effect of BMI on endometrial cancer risk (OR = 1.55; 95% CI, 1.44-1.68, per 5 kg/m2). The association attenuated but remained significant after adjusting for BMI (OR = 1.22; 95% CI, 1.10-1.39; P = 5.3 × 10-4). There was evidence of directional pleiotropy (P = 1.5 × 10-4). BMI SNP rs2075650 was associated with endometrial cancer at study-wide significance (P < 4.0 × 10-4), independent of BMI. Endometrial cancer was not significantly associated with individual WHR SNPs or the WHRwGRS.

CONCLUSIONS:

BMI, but not WHR, is causally associated with endometrial cancer risk, with evidence that some BMI-associated SNPs alter endometrial cancer risk via mechanisms other than measurable BMI. IMPACT The causal association between BMI SNPs and endometrial cancer has possible implications for endometrial cancer risk modeling. Cancer Epidemiol Biomarkers Prev; 25(11); 1503-10. ©2016 AACR.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Índice de Masa Corporal / Neoplasias Endometriales / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Análisis de la Aleatorización Mendeliana / Obesidad Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Asunto de la revista: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Índice de Masa Corporal / Neoplasias Endometriales / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Análisis de la Aleatorización Mendeliana / Obesidad Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Asunto de la revista: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Australia